Anixa biosciences Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Anixa biosciences Contact Number

Contact Us :: Anixa Biosciences, Inc. (ANIX)

9 hours ago Anixa.com Show details

Contact Us; Contact Us. Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118. Sign up for email Updates. Be The First to Receive Breaking News. Sign Up Now. Latest News & Events. Oct 6, 2021. Anixa Biosciences Announces First Chinese Patent on …

Category: Contact SupportShow more

ANIX Anixa Biosciences Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

408-708-9808Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Contact: Mike Catelani [email protected]anixa.com 408-708-9808. View original content to download multimedia: About Anixa Biosciences, Inc.

Category: Contact NumberShow more

Anixa Biosciences Crunchbase Company Profile & Funding

8 hours ago Crunchbase.com Show details

Phone Number 6315495974. Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer

Founded: 1982

Category: Contact NumberShow more

Investors :: Anixa Biosciences, Inc. (ANIX)

1 hours ago Ir.anixa.com Show details

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.

Category: Contact NumberShow more

Overview :: Anixa Biosciences, Inc. (ANIX)

6 hours ago Anixa.com Show details

Anixa is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function.

Category: Contact NumberShow more

Anixa Biosciences, Inc. (ANIX) Company Profile & Overview

6 hours ago Stockanalysis.com Show details

Company profile for Anixa Biosciences, Inc. (ANIX) with a description, list of executives, contact details and other key facts. Company profile for Anixa Biosciences, Inc. (ANIX) with a description, list of executives, contact details and other key facts. CUSIP Number: 03528H109: ISIN Number: US03528H1095: Employer ID: 11-2622630: Key

Category: Contact NumberShow more

Anixa Biosciences Company Profile Office Locations

3 hours ago Craft.co Show details

Anixa Biosciences has 7 employees at their 1 location. See insights on Anixa Biosciences including office locations, competitors, revenue, financials, executives, subsidiaries and …

Category: Contact NumberShow more

Press Releases :: Anixa Biosciences, Inc. (ANIX)

6 hours ago Ir.anixa.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

ANIX Stock Forecast, Price & News (Anixa Biosciences)

6 hours ago Marketbeat.com Show details

(408) 708-9808How can I contact Anixa Biosciences? Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118 . The company can be reached via phone at (408) 708-9808 or via email at [email protected] .

Category: Contact NumberShow more

ANIXA BIOSCIENCES INC Number of Employees 20062021 ANIX

8 hours ago Macrotrends.net Show details

355 rows · ANIXA BIOSCIENCES INC number of employees from 2006 to 2021. Number of …

Category: Contact NumberShow more

ANIX TW Research Group

3 hours ago Twresearchgroup.com Show details

Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing. Daniel Carlson - December 14, 2020. 1. SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

3 hours ago Wdtv.com Show details

Contact Us. Meet the Team. About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa

Category: Contact NumberShow more

Anixa Biosciences and Moffitt Cancer Center Report US FDA

4 hours ago Ih.advfn.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

3 hours ago Whsv.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a

Category: Contact NumberShow more

ANIXA BIOSCIENCES, INC. : Shareholders Board Members

2 hours ago Marketscreener.com Show details

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on oncology and infectious disease.

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

8 hours ago Finance.yahoo.com Show details

Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today …

Category: Contact NumberShow more

Anixa Biosciences : and Moffitt Cancer Center Announce FDA

7 hours ago Marketscreener.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

KUMAR AMIT SC 13D/A Filing Concerning ANIX on 20210830

5 hours ago Whalewisdom.com Show details

021-09-03ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Amit Kumar. c/o Anixa Biosciences, Inc. 3150 Almaden Expressway, Suite 250. San Jose, CA 90025 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 30, 2021

Category: Contact NumberShow more

Anixa Biosciences' Covid19 Compounds Expected to be

2 hours ago Finance.yahoo.com Show details

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates

Category: Contact NumberShow more

Anixa Biosciences How Have the Numbers Shaped Up for Stock

2 hours ago Stockmarketdaily.co Show details

Anixa Biosciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $11.00, Anixa Biosciences has a forecasted upside of 190.2% from its current price of $3.79.

Category: Contact NumberShow more

10 Best Biotech Stocks Under $10 Insider Monkey

4 hours ago Insidermonkey.com Show details

As of Q2 2021, 2 hedge funds tracked by Insider Monkey have positions in Anixa Biosciences, Inc. (NASDAQ: ANIX), worth $722,000. The number of hedge funds remained the same in the previous quarter

Category: Tech SupportShow more

Anixa Biosciences' Covid19 Compounds Expected to be

3 hours ago Prnewswire.com Show details

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant. SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ -- Anixa Biosciences

Category: Contact NumberShow more

Anixa Biosciences Covid19 Therapy Demonstrates Comparable

Just Now Prnewswire.com Show details

SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today

Category: Contact NumberShow more

Anixa Biosciences and Moffitt Cancer Center Receive

7 hours ago Stocktitan.net Show details

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on

Category: Contact NumberShow more

Kent Bennett Williams, Chief Executive Officer & Principal

9 hours ago Relationshipscience.com Show details

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities.

Category: Contact NumberShow more

Anixa Biosciences Inc ANIX FormWhispers

3 hours ago Formwhispers.com Show details

Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.

Category: Contact NumberShow more

Emily Gottschalk Net Worth, Biography & Insider Trading

5 hours ago Insidertrades.com Show details

(408) 708-9808How do I contact Emily Gottschalk? The corporate mailing address for Ms. Gottschalk and other Anixa Biosciences executives is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. Anixa Biosciences can also be reached via phone at (408) 708-9808 and via email at [email protected]

Category: Contact NumberShow more

How to buy Anixa Biosciences stock 21 Oct price $4.34

3 hours ago Finder.com Show details

Since the stock market crash in March caused by coronavirus, Anixa Biosciences's stock price has had significant positive movement. Its last market close was $4.34, which is 22.12% up on its pre-crash value of $3.38 and 226.32% up on the lowest point reached during the March crash when the stocks fell as low as $1.33.

Category: Contact NumberShow more

OntoChem GmbH Anixa to Host a Conference Call to Discuss

2 hours ago Ontochem.com Show details

Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, “There are a number of drugs that are either in, or will shortly be in, clinical trials against COVID-19. While we unquestionably hope one or more of those drugs is successful, we must note that all those drugs were developed for other viruses and other diseases.

Category: Contact NumberShow more

Anixa Biosciences' Ovarian Cancer CART Therapy to be

3 hours ago Apnews.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

Lantern Pharma TW Research Group

3 hours ago Twresearchgroup.com Show details

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress. DALLAS, July 30, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to …

Category: Contact NumberShow more

National Cancer Institute Investments, Portfolio

4 hours ago Crunchbase.com Show details

National Cancer Institute has made 50 investments. Their most recent investment was on Sep 28, 2021, when Senti Biosciences raised $1.9M. National Cancer Institute has made 9 diversity investments. Their most recent diversity investment was on Apr 5, 2021, when care.coach raised National Cancer Institute has had 6 exits.

Category: Contact NumberShow more

Anixa Biosciences, Inc. (ANIX) Stock Price Today, Quote

6 hours ago Seekingalpha.com Show details

How can I contact Anixa Biosciences, Inc.? Anixa Biosciences, Inc.’s mailing address is 3150 Almaden Expressway, San Jose CA 95118, United States. They can …

Category: Contact NumberShow more

This Biotech Stock is a "Buy" Above $4.40 Trades Of The Day

7 hours ago Tradesoftheday.com Show details

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutics portfolio includes a cancer immunotherapy program that uses a novel type of CAR-T technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.

Category: Tech SupportShow more

Anixa Biosciences Price Target, Predictions & Analyst Ratings

9 hours ago Marketbeat.com Show details

According to the issued ratings of 2 analysts in the last year, the consensus rating for Anixa Biosciences stock is Buy based on the current 2 buy ratings for ANIX. The average twelve-month price target for Anixa Biosciences is $11.00 with a high price target of $11.00 and a low price target of $11.00. Learn more. on ANIX's analyst rating history.

Category: Contact NumberShow more

Anixa Biosciences Inc (ANIX) 10K Annual Reports & 10Q SEC

6 hours ago Last10k.com Show details

Inside Anixa Biosciences Inc's 10-K Annual Report: Other - Other Highlight 35 The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $98,000 to approximately $74,000 in fiscal year 2020, from approximately $172,000 in fiscal year 2019, as Certainty's net loss decreased.

Category: Contact NumberShow more

Anixa Biosciences Announces Notice of Allowance for

5 hours ago Apnews.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

Anixa and OntoChem Announce Identification of Additional

8 hours ago Biospace.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

Commercial Launch of Liquid Biopsy Test for Detection of

6 hours ago Targetedonc.com Show details

The Cchek Prostate Cancer Confirmation test—which utilizes artificial intelligence, flow cytometry, and liquid-biopsy technology to detect prostate cancer—has been commercially launched, according to Anixa Biosciences, Inc., developer of the test. Once it becomes available, this test will reduce the need for expensive and invasive biopsy procedures to diagnose patients with prostate …

Category: Contact NumberShow more

Anixa Biosciences Announces Issuance and Publication of

9 hours ago Stocktitan.net Show details

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on

Category: Contact NumberShow more

Howland v. Kumar Delaware Business Court Insider

7 hours ago Law.com Show details

Case Number: D68611; Case Digest Summary Plaintiff was a stockholder of Anixa Biosciences, Inc. In 2017, Anixa's officers and directors repriced stock …

Category: Contact NumberShow more

Anixa Biosciences Congratulates Director, Dr. Arnold

2 hours ago Ih.advfn.com Show details

About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

ANIX Stock Price and Chart — NASDAQ:ANIX — TradingView

8 hours ago Tradingview.com Show details

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities.

Category: Contact NumberShow more

Breast cancer vaccine Anixa Biosciences/Cleveland Clinic

8 hours ago Adisinsight.springer.com Show details

01 Dec 2020 Anixa Biosciences plans clinical trials for Breast cancer (Prevention) in early 2021 Subscriber content You need to be a logged in subscriber to view this content.

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

2 hours ago Pipelinereview.com Show details

9 hours ago · About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

Just Now Biospace.com Show details

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

6 hours ago Markets.businessinsider.com Show details

1 day ago · Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study …

Category: Contact NumberShow more

Anixa Biosciences Announces Patient Dosing of its

3 hours ago Nypressnews.com Show details

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of biotechnology company is Anixa Biosciences?

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.

When is Anixa Biosciences next earnings release date?

Anixa Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021. View our earnings forecast for Anixa Biosciences. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) released its quarterly earnings results on Wednesday, June, 9th.

What are the analysts price targets for Anixa?

Their forecasts range from $11.00 to $11.00. On average, they anticipate Anixa Biosciences' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 176.4% from the stock's current price. View analysts' price targets for Anixa Biosciences or view top-rated stocks among Wall Street analysts.

What is the support level for Anix stock?

Reversed on 2.81 resistance. 250RSI below 50 = bearish 200MA pointing south = bearish If confirmed, should see some move South. Target #1 = 1.51 $ support level Target #2 = 0.66 $ support level Very simple set up for direction confirmation. I have a large position in this stock for 2 weeks.

Popular Brands

Amazon
Abbvie
Aia
Asml
Apple
Att
Amgen
Adobe
Aptar
Acc
Adidas
Aak
Aes
Asx